Geoffrey Porges, analyst at Leerink Partners is positive about the success of Gilead Sciences (NASDAQ: GILD), as the only risks involved are the revenue erosion associated with the expiration of the Viread patent license ending in 2018, and competitive new brands in the HIV category. Porges maintained the price target of $125 along with an Outperform rating for the stock, respective to its persistence and continued growth in HIV drug franchise.

Porges narrated his opinions ahead of the shortly arriving annual Conference for Retroviruses and Opportunistic Infections (CROI). According to Leerink Partners, the CROI meeting will perhaps focus on HIV patients with higher complexity, and also declare Hepatitis B drug, TAF, plans safe.

The analyst gave his opinion based on multiple important factors, which include: concerns surrounding TAF drug safety data to remain positive for different samples and significant inroads can be made by using the additional data. Data from pre-mature HIV patients will be crucial in determining the long term benefits as it is indicated that present drugs are not effective in meeting the medical requirements for such. Merck and Viv parental formula’s impact is yet to be seen, however, data shows some promise. Increase in usage of pre-exposure HIV prophylaxis presents a positive vibe, and lastly the enhanced scrutiny measure by drug authorities for the approval of new compounds restricts short term impact to a minimum.

Analyst opinion for the stock is largely divided with five Strong Buy and nine Buy ratings. Of the remaining seven analysts, six have rated the stock as a Hold and only one analyst has given the stock an Underperform rating. The stock is currently trading at $88.97.